Saturday, March 25, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Army Moves Forward on Topical Drug for Cutaneous Leishmaniasis

by Global Biodefense Staff
August 2, 2012

The U.S. Army Medical Material Development Activity (USAMMDA) yesterday announced its intent to award a sole source contract to Fast Track Drugs and Biologics to assist USAMMDA’s drug development and approval efforts for a topical to treat Cutaneous Leishmaniasis.

USAMMDA has for several years been working on a Topical Paromomycin Cream for self-treatment of Cutaneous Leishmaniasis, a serious parasitic disease caused by protozoan parasites. It is transmitted to humans through the bite of an infected sand fly in tropical and subtropical zones, including the Middle East. Although Leishmaniasis is usually a non-life threatening disease, it can be mutilating and disfiguring.

Current traditional treatments for Leishmaniasis require intravenous or intralesional administration of toxic, heavy metal-based drugs (antimonials). In the United States, this is an investigational treatment that involves 10-20 days of daily IV infusions under close physician monitoring in a hospital. This treatment course involves many side effects and toxicities, including vomiting, diarrhea, pancreatitis, elevated liver enzymes, and potentially pulmonary edema at higher doses.

From 2003 to present, more than 1,100 U.S. servicemembers have required such treatment for Leishmaniasis. In addition to the unwanted side effects, the disease therapy is expensive and requires troops to be evacuated from their units and brought to the U.S. for treatment.

The World Health Organization (WHO) has endorsed treatment with topical paromomycin formulations as first-line therapy for Cutaneous Leishmaniasis, and the USAMMDA Topical Paromomycin product is poised to be the first such solution for the broader worldwide community.

Topical Paromomycin’s United States and International development partners include: USAMMDA; Walter Reed Army Institute of Research (WRAIR); the Institut Pasteur de Tunis, the Institut Pasteur – Paris; the Gorgas Memorial Institute for Health Studies – Panama City, Panama; the Universidad Peruana Cayetano Heredia – Lima, Peru; Naval Medical Research Detachment – Peru; and the Walter Reed National Military Medical Center (WRNMMC).

U.S. Army Medical Research Acquisition Activity (USAMRAA) is managing the contract under Solicitation Number: W806YH21816001.

Tags: AwardsLeishmaniasisWRAIR

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC